Lupin gets USFDA nod for generic anti-depressant tablets
New Delhi : Lupin has received tentative approval for its generic version of anti-depressant Paroxetine extended-release tablets from the US health regulator.
The tentative approval by the United States Food and Drug Administration (USFDA) is for multiple strengths of 12.5 mg, 25 mg and 37.5 mg of the generic version of Apotex Technologies' Paxil CR tablets of similar strengths, Lupin said in a BSE filing.
The drug is indicated for the treatment of major depressive disorders, panic disorders, social anxiety disorders and premenstrual dysphoric disorders.
Citing IMS MAT data till June 2016, Lupin said Paxil CR had US sales of $127.4 million.
Shares of Lupin were trading down by 0.46 per cent at Rs 1,515.60 on the BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd